Q-omics provides the consensus-scored SEMA3E profile across patient tissues and cancer cell-line models. SEMA3E expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SEMA3E is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SEMA3E RNA expression shows 16,814 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where SEMA3E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA3E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA3E survival associations across molecular data types. SEMA3E RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA3E RNA expression–survival associations across cancer types. High SEMA3E expression shows unfavorable associations in UVM, KIRC, LGG and STAD, but favorable associations in UCS and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SEMA3E RNA expression.
This table summarizes SEMA3E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SEMA3E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA3E shows lower tumor expression in BLCA, COAD, LUSC, HNSC, READ and LUAD. The BLCA box plot shows higher SEMA3E RNA expression in normal versus tumor tissue (log2 FC = −2.746, t-test p < 0.001).
This table shows molecular features associated with SEMA3E in patient tissues and cancer cell lines. In patient samples, SEMA3E shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA3E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
